Spots Global Cancer Trial Database for Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus
Official Title: Radiotherapy & Olaparib in COmbination for Carcinoma of the Oesophagus. A Phase I Trial.
Study ID: NCT01460888
Conditions
Study Description
Brief Summary: The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of olaparib in combination with radical radiotherapy in patients with oesophageal cancer who are unsuitable for platinum containing chemotherapy.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Christie NHS Foundation Trust, Manchester, , United Kingdom
Southampton General Hospital, Southampton, , United Kingdom
Contact Details
Name: Andrew Jackson, Dr
Affiliation: University Hospital Southampton NHS Foundation Trust
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
